Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02251873
Recruitment Status : Completed
First Posted : September 29, 2014
Last Update Posted : September 29, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to characterise the effects of concurrent tipranavir (TPV) and ritonavir (RTV) administration on the single dose pharmacokinetics of didanosine (ddI), to characterise the effects of single-dose ddI on the pharmacokinetics of TPV and RTV and to assess the short-term safety of this combination

Condition or disease Intervention/treatment Phase
Healthy Drug: TPV + RTV (low dose) Drug: TPV + RTV (high dose) Drug: ddl Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules) 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Both Bid for 13.5 Days With Single Dose Didanosine 400 mg (Delayed Release Capsule EC Beadlets) in Healthy Volunteers
Study Start Date : September 2001
Actual Primary Completion Date : March 2002

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TPV + RTV (low dose)+ ddI Drug: TPV + RTV (low dose)
Drug: ddl
Experimental: TPV+ RTV (high dose)+ ddI Drug: TPV + RTV (high dose)
Drug: ddl



Primary Outcome Measures :
  1. (AUC 0-12) Area under the plasma concentration time curve from 0-12 hours [ Time Frame: up to 12 hours after dose administration ]
  2. Cmax (Maximum measured concentration of the analyte in plasma) [ Time Frame: up to 12 hours after dose administration ]
  3. (C6h) drug concentration in plasma at 6 hours after drug administration [ Time Frame: up to 6 hours after dose administration ]
  4. (C12h) drug concentration in plasma at 12 hours after drug administration [ Time Frame: up to 12 hours after dose administration ]
  5. Cnh (plasma concentration n hours after drug administration) [ Time Frame: up to 12 hours after dose administration ]

Secondary Outcome Measures :
  1. Cmax,ss (maximum plasma concentration at steady state) [ Time Frame: up to 12 hours after dose administration ]
  2. MRT (mean residence time) [ Time Frame: up to 12 hours after dose administration ]
  3. Tmax (time to the maximum plasma concentration) [ Time Frame: up to 12 hours after dose administration ]
  4. CL/F (apparent oral clearance) [ Time Frame: up to 12 hours after dose administration ]
  5. Vz/F (apparent volume of distribution) [ Time Frame: up to 12 hours after dose administration ]
  6. t½ (Terminal half-life of the analyte in plasma) [ Time Frame: up to 12 hours after dose administration ]
  7. Number of subjects with adverse events [ Time Frame: up to 40 days ]
  8. Number of subjects with abnormal changes in laboratory parameters [ Time Frame: up to 40 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or female subjects as determined by results of screening
  • Female subjects were not lactating and not of child bearing potential as defined by surgically sterile or post menopausal (no periods for at least 12 months and elevated follicle stimulating hormone (FSH) with low estradiol and no estrogen supplementation). Females were to use barrier contraception (e.g. condoms) for at least one month prior to administration of study medication, during the study and at least one month after release from the study. Women were to have negative pregnancy tests
  • Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
  • Age >=18 and <=60 years
  • Body mass index (BMI) >=18.5 and <=29.9 kg/m2

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders, including a clinical history of viral hepatitis, or serological evidence of active Hepatitis B, Hepatitis C, or HIV infection
  • History of orthostatic hypotension, fainting spells and blackouts
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator including study drugs
  • Intake of drugs with a long half-life (> 24 hours) or enzyme altering drug within 1 month prior to administration of study drugs
  • Use of any drugs that might have influenced the results of the trial within 10 days prior to administration or during the trial (in addition to specific medication prohibitions mentioned in exclusion criteria above)
  • Use of grapefruit or grapefruit juice, alcohol, green tea, methylxanthine-containing products or tobacco within one week of study drug administration
  • Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
  • Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on trial days
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood or plasma donation within 1 month prior to administration or during the trial
  • Excessive physical activities within 5 days prior to administration or during the trial
  • Following specific laboratory findings: activated partial thromboplastin time (aPTT), prothrombin time international normalised ratio (INR), aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl-transferase (GGT), amylase, lipase, or triglyceride above the normal range
  • Any other laboratory value outside the clinically accepted reference range and of clinical relevance
  • History of any familial bleeding disorder
  • Inability to swallow multiple large capsules
  • Inability to comply with dietary regimen of study centre
  • Inability to comply with investigator's instructions

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02251873     History of Changes
Other Study ID Numbers: 1182.42
First Posted: September 29, 2014    Key Record Dates
Last Update Posted: September 29, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Ritonavir
Didanosine
Tipranavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Antimetabolites
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors